Rhythm Pharmaceuticals, Inc.

BMV:RYTM * Stock Report

Market Cap: Mex$75.7b

Rhythm Pharmaceuticals Management

Management criteria checks 2/4

Rhythm Pharmaceuticals' CEO is David Meeker, appointed in Jul 2020, has a tenure of 4.5 years. total yearly compensation is $7.23M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth MX$214.94M. The average tenure of the management team and the board of directors is 4.2 years and 5.6 years respectively.

Key information

David Meeker

Chief executive officer

US$7.2m

Total compensation

CEO salary percentage9.7%
CEO tenure4.5yrs
CEO ownership0.3%
Management average tenure4.2yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Meeker's remuneration changed compared to Rhythm Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$262m

Jun 30 2024n/an/a

-US$261m

Mar 31 2024n/an/a

-US$274m

Dec 31 2023US$7mUS$705k

-US$185m

Sep 30 2023n/an/a

-US$186m

Jun 30 2023n/an/a

-US$182m

Mar 31 2023n/an/a

-US$181m

Dec 31 2022US$3mUS$652k

-US$181m

Sep 30 2022n/an/a

-US$181m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$166m

Dec 31 2021US$6mUS$630k

-US$70m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$15mUS$262k

-US$134m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$134m

Mar 31 2020n/an/a

-US$146m

Dec 31 2019US$287kn/a

-US$141m

Sep 30 2019n/an/a

-US$133m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$87m

Dec 31 2018US$282kn/a

-US$74m

Compensation vs Market: David's total compensation ($USD7.23M) is above average for companies of similar size in the MX market ($USD1.33M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Meeker (70 yo)

4.5yrs

Tenure

US$7,230,457

Compensation

Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...

Leadership Team

NamePositionTenureCompensationOwnership
David Meeker
Chairman4.5yrsUS$7.23m0.28%
MX$ 214.9m
Hunter Smith
CFO & Treasurer7.5yrsUS$2.31m0.16%
MX$ 120.6m
Joseph Shulman
Chief Technical Officer4.5yrsUS$1.74m0%
MX$ 0
Yann Mazabraud
Executive VP & Head of International4.3yrsUS$1.74m0.057%
MX$ 42.9m
Jennifer Lee
Executive VP & Head of North America4.2yrsUS$2.11m0.0016%
MX$ 1.2m
Christopher German
Corporate Controller1.8yrsno data0.0013%
MX$ 975.9k
Alastair Garfield
Chief Scientific Officerless than a yearno datano data
David Connolly
Head of Investor Relations & Corporate Communicationsno datano datano data
Jim Flaherty
Senior VP & General Counsel4.2yrsno datano data
Sarah Ryan
Vice President of Sales & Marketingno datano datano data
Pamela Cramer
Chief Human Resources Officer3.5yrsno data0.022%
MX$ 16.6m
Elisabeth Cronert-Bendell
Senior VP & Head of Strategy2.9yrsno datano data

4.2yrs

Average Tenure

51yo

Average Age

Experienced Management: RYTM *'s management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Meeker
Chairman9.2yrsUS$7.23m0.28%
MX$ 214.9m
Christopher German
Corporate Controller1.8yrsno data0.0013%
MX$ 975.9k
Jennifer Good
Independent Director5.6yrsUS$283.77k0.0049%
MX$ 3.7m
David W. McGirr
Independent Director9.2yrsUS$308.77k0.0049%
MX$ 3.7m
Edward Mathers
Lead Independent Director11.8yrsUS$328.77k0.014%
MX$ 10.8m
Lynn Tetrault
Independent Director4.1yrsUS$298.77k0.0049%
MX$ 3.7m
William Chin
Member of Scientific Advisory Boardno datano datano data
Elizabeth Stoner
Member of Scientific Advisory Boardno datano datano data
Michael Camilleri
Member of Scientific Advisory Boardno datano datano data
Lee Kaplan
Chairman of Scientific Advisory Boardno datano datano data
John Amatruda
Member of Scientific Advisory Boardno datano datano data
Stuart Arbuckle
Independent Director5.5yrsUS$301.27k0.0049%
MX$ 3.7m

5.6yrs

Average Tenure

67yo

Average Age

Experienced Board: RYTM *'s board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 14:48
End of Day Share Price 2024/11/04 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rhythm Pharmaceuticals, Inc. is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Whitney IjemCanaccord Genuity
Corinne JohnsonGoldman Sachs